PARIS, October 28, 2016 /PRNewswire/ --
Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2016. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on the results.
Watch video interview and read transcript:
https://www.eurobusinessmedia.com/video/sanofi-q3-2016-results/?utm_source=ceo-direct&utm_medium=wire Topics covered in the interview include:
- Q3 highlights
- Cost savings
- Diabetes
- Capital allocation
- Portfolio
- Dengvaxia(R)
- Outlook
About Sanofi:
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
SOURCE Sanofi
Advertisement
Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2016. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on the results.
Advertisement
Watch video interview and read transcript:
https://www.eurobusinessmedia.com/video/sanofi-q3-2016-results/?utm_source=ceo-direct&utm_medium=wire Topics covered in the interview include:
- Q3 highlights
- Cost savings
- Diabetes
- Capital allocation
- Portfolio
- Dengvaxia(R)
- Outlook
About Sanofi:
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
SOURCE Sanofi
